Vetter’s Development Service (VDS) has expanded its capabilities in Chicago, IL and Ravensburg, Germany, and has grown to more than 150 scientists, engineers and other personnel. Vetter’s Chicago facility provides early-stage clinical production, featuring equipment optimized for small-batch manufacturing, while the Ravensburg facilities support a range of development products through Phase III.
Since the launch of the Chicago site in October 2011, VDS has expanded analytical and microbial testing, added 2,000 sq. ft. of GMP storage, and expanded its office to accommodate more than 20 additional personnel. Future plans include adding a third cleanroom, which will expand current operations and provide filling of pre-sterilized syringes.
The company has also acquired new technologies at its Ravensburg development labs, aimed at providing better control of syringe and cartridge siliconization, more-accurate detection of sub-visible particles in drug products, and a greater ability to simulate commercial-level processes.
Paul Nelles, Ph.D., vice president of VDS, said, “The growth of VDS demonstrates the increasing need for expert support in the development of complex compounds, to address a growing market. This rise in demand confirms our decision to expand Vetter Development Service to North America, as was urged by our U.S.-based customers.”